Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada

Alexander Diamantopoulos; Michael Lees; Philip S. Wells; Fiona Forster; Jaithri Ananthapavan; Heather McDonald

doi:10.1160/TH10-01-0071

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2010; 104(04): 760-770
DOI: 10.1160/TH10-01-0071

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada

Alexander Diamantopoulos

¹Symmetron Limited, London, UK

,

Michael Lees

³Bayer HealthCare, Uxbridge, UK

,

Philip S. Wells

⁴Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

,

Fiona Forster

²IMS Health, London, UK

,

Jaithri Ananthapavan

²IMS Health, London, UK

,

Heather McDonald

⁵Bayer Inc., Toronto, Ontario, Canada

› Institutsangaben

Abstract

Summary

This study aimed to evaluate the cost-effectiveness of prophylaxis with rivaroxaban vs. enoxaparin in the prevention of venous thromboembolism (VTE) after total hip replacement (THR) and total knee replacement (TKR) from the perspective of the Canadian healthcare system. A model was developed that included both acute VTE (represented as a decision tree) and long-term complications (represented as a Markov process with one-year cycles). Transition probabilities were derived from phase III clinical trials comparing rivaroxaban with enoxaparin and published literature. Costs were derived from the Ontario Case Costing Initiative and publicly available sources. Utilities were derived from published literature. The model reported VTE event rates, quality-adjusted life expectancy and direct medical costs over a five-year horizon. Costs are reported in 2007 Canadian Dollars (C$). When rivaroxaban and enoxaparin are compared in patients undergoing THR, rivaroxaban dominates enoxaparin. That is, rivaroxaban is associated with improved health outcomes as measured by increased quality-adjusted life years (QALYs; 0.0006) and fewer symptomatic VTE events (0.0061), and also with lower cost (savings of C$300) per patient. Similarly, rivaroxaban dominates enoxaparin in patients undergoing TKR, achieving a gain of 0.0018 QALYs, a reduction of 0.0192 symptomatic venous thromboembolic events and savings of C$129 per patient. Rivaroxaban is a cost-effective alternative to enoxaparin for VTE prophylaxis in patients undergoing THR and TKR. Over a five-year horizon, rivaroxaban dominated enoxaparin in the prevention of VTE events in patients undergoing THR and TKR, providing more quality-of-life benefit at a lower cost.

Keywords

Anticoagulants - surgery - thrombosis

Volltext

Referenzen

References
1 Heit JA, Melton III LJ, Lohse CM. et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 2001; 76: 1102-1110.
2 Turpie AG, Norris TM. Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin. Thromb Haemost 2004; 92: 3-12.
3 Blann AD, Lip GY. Venous thromboembolism. Br Med J 2006; 332: 215-219.
4 Malone PC, Agutter PS. The aetiology of deep venous thrombosis. QJM 2006; 99: 581-593.
5 Tapson VF. Acute pulmonary embolism. N Engl J Med 2008; 358: 1037-1052.
6 Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 2009; 29: 298-310.
7 Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 2004; 164: 17-26.
8 Pengo V, Lensing AW, Prins MH. et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-2264.
9 Jaffer AK. An overview of venous thromboembolism: impact, risks, and issues in prophylaxis. Cleve Clin J Med 2008; 75 (Suppl. 03) S3-S6.
10 Deitelzweig SB, McKean SC, Amin AN. et al. Prevention of venous thromboembolism in the orthopedic surgery patient. Cleve Clin J Med 2008; 75 (Suppl. 03) S27-S36.
11 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
12 Hip and knee replacements in Canada. 2008–2009 Annual Report. (Accessed July 31, 2009, at http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_page=AR_30_E. )
13 Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. NICE clinical guidelines 46. (Accessed March 31, 2009, at http://www.nice.org.uk/nicemedia/pdf/CG046NICEguideline.pdf. )
14 Perzborn E, Kubitza D, Misselwitz F. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. Hamostaseologie 2007; 27: 282-289.
15 Graff J, von Hentig N, Misselwitz F. et al. Effects of the oral, direct Factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007; 47: 1398-1407.
16 Eriksson BI, Borris LC, Friedman RJ. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
17 Kakkar AK, Brenner B, Dahl OE. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
18 Lassen MR, Ageno W, Borris LC. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
19 Turpie AGG, Lassen MR, Davidson BL. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-1680.
20 Turpie AG, Bauer KA, Davidson BL. et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009; 101: 68-76.
21 Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009; 101: 77-85.
22 Sullivan SD, Kahn SR, Davidson BL. et al. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics 2003; 21: 477-496.
23 Quinlan DJ, Eikelboom JW, Dahl OE. et al. Association between asymptomatic deep-vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost 2007; 5: 1438-1443.
24 Life Tables, Canada, Provinces and Territories 2000 to 2002. (Accessed May 27, 2010, at http://www.statcan.gc.ca/bsolc/olc-cel/olc-cel?catno=84–537-XIE&lang=eng. )
25 White RH, Romano PS, Zhou H. et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 1525-1531.
26 Prandoni P, Villalta S, Bagatella P. et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997; 82: 423-428.
27 Prandoni P, Hutten BA, van Dongen CJ. et al. Quality of oral anticoagulant treatment and risk of subsequent recurrent thromboembolism in patients with deep vein thrombosis. J Thromb Haemost 2007; 5: 1555.
28 Buller HR, Davidson BL, Decousus H. et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-1702.
29 Kearon C, Ginsberg JS, Anderson DR. et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004; 2: 743-749.
30 Rasanen P, Paavolainen P, Sintonen H. et al. Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs. Acta Orthop 2007; 78: 108-115.
31 Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc 1997; 4: 49-56.
32 Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Arch Orthop Trauma Surg 2004; 124: 507-517.
33 Harrison L, McGinnis J, Crowther M. et al. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998; 158: 2001-2003.
34 Skedgel C, Goeree R, Pleasance S. et al. The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty. J Bone Joint Surg Am 2007; 89: 819-828.
35 Anonymous.. OCCI Acute Inpatient Databases 2005/06 and 2006/07. 2007
36 Ministry of Health and Long Term Care.. Ontario Schedule of Benefits: Physician services under the Health Insurance Act. (November 19, 2007 effective February 1, 2008). 2008
37 Anonymous.. Ontario Drug Benefit Formulary. 2008
38 Kind P, Dolan P, Gudex C. et al. Variations in population health status: results from a United Kingdom national questionnaire survey. Br Med J 1998; 316: 736-741.
39 Anonymous.. Ontario Association of Community Care Access Centres (OACCAC). 2010
40 Medical Services Commission Payment Schedule. (Accessed April 1, 2008, at http://www.hlth.gov.bc.ca/msp/infoprac/physbilling/payschedule/index.html. )
41 Caprini JA, Botteman MF, Stephens JM. et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003; 6: 59-74.